INOVIO Pharmaceuticals Inc. (NASDAQ:INO) shares fell 10% in early trading after the biotech company announced the pricing of ...

Investors might want to bet on Inovio Pharmaceuticals (INO), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...

Inovio Pharmaceuticals marked a significant milestone by completing the rolling submission of the Biologics License Application (BLA) for INO-3107. This achievement underscores the company’s ...

Inovio Pharmaceuticals Inc (INO) showcases significant progress in its BLA submission for INO-3107, while navigating ...

Inovio Pharmaceuticals (INO) reported a disappointing 3Q25 with a GAAP EPS loss of -$0.87, missing consensus by $0.45 and ...

Inovio Pharmaceuticals (NASDAQ:INO) is preparing to release its quarterly earnings on Thursday, 2024-11-14. Here's a brief overview of what investors should keep in mind before the announcement.

Inovio Pharmaceuticals Inc. closed 57.05% below its 52-week high of $4.61, which the company reached on December 3rd.

Novavax just signed a lucrative agreement with a biotech giant. Inovio Pharmaceuticals is inching closer to launching its leading candidate. Both companies look risky, but one has a clear edge over ...

Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday’s session. The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses. See the ...

Usually when a clinical-stage biotech announces that a planned clinical study is being scrapped, it's bad news. But when Inovio Pharmaceuticals stated on March 29 that it would not move forward with ...

Inovio Pharmaceuticals shares are trading higher by 17.9% Tuesday afternoon. Vaccine stocks are rising amid growing concerns about respiratory illnesses. The next correction is closer than you think.

The COVID-19 vaccine was worth tens of billions of dollars, but most of it went into the hands of Moderna and Pfizer. Smaller biotechs that tried to dominate this market were much less successful.